The US market for Hemostats and Sealants continued back toward its pre-pandemic levels, gaining +20.0% QoQ and up +1.1% YoY. For FY20, the market declined, as COVID-19 delayed procedures in Q220 proved too much to overcome.
Among the many topics covered in the comprehensive Q420/FY20 US Hemostats and Sealants Market Recap* are:
- Complete US Hemostats & Sealants Market Overview
- Companies' Revenues and Market Shares
- US Hemostats and Sealants Market Exceeds Pre-Pandemic Level
- Thrombin Hemostats Pull Ahead
- Fibrin Sealants Lead The Recovery
- Important Q420 US Hemostats and Sealants Events
Approximately, half of the companies in the market experienced losses for the quarter, though Ethicon* managed a +4.6% YoY gain in Q420 and Integra eked out a +2.2% YoY gain. For the full year, all manufacturers saw revenue declines ranging from ...
Read the entire Q420/FY20 US Hemostats and Sealants Market Recap including news, data, charts, company revenues, shares and analysis*
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis. Used by the 15 top Advanced Wound Care companies and 8 of the 10 top Orthopedic companies, SmartTRAK transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.
